Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
Future Virology, one of our partner journals, has published a Short Communication on the results from a Phase II study of bemnifosbuvir, a novel nucleotide analogue to inhibit the replication of SARS-CoV-2.
Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication.
Materials & methods: Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two-parts after interim analysis; part B enrollment limited owing to evolving standard of care.
Results: Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61 log10 greater viral load mean change on day 2; trend sustained through day 8. Treatment-emergent adverse events were similar in both groups; most were mild/moderate, unrelated to study drug.
Conclusion: Our results suggest a potential role for bemnifosbuvir in blunting COVID-19 progression.
Clinical Trial Registration: NCT04396106 (ClinicalTrials.gov)
This post was supported by Atea Pharmaceuticals
